UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition

In the largest acquisition successful the medtech assemblage frankincense acold this year, Abbott Laboratories (NYSE:ABT) signed a ceremonial statement to bargain Exact Sciences astatine $105 per share. The woody is scheduled for completion successful the 2nd 4th of 2026. Abbott’s Diagnostics part is expected to emergence by astir 300 ground points arsenic a effect of the transaction.

Abbott’s aesculapian instrumentality businesses, which are chiefly focused connected diabetes and cardiovascular disease, volition present task into crab attraction with this acquisition. Abbott Laboratories (NYSE:ABT) volition besides adhd Exact Sciences’ flagship test, Cologuard, which screens for colorectal cancer, to its portfolio.

Beyond Diagnostics, UBS is adamant that Abbott Laboratories (NYSE:ABT) volition consistently outperform its competitors successful income and net per stock starting successful 2026, fixed its aesculapian exertion illustration and persistent double-digit growth.

Abbott Laboratories (NYSE:ABT) is simply a starring planetary healthcare institution that manufactures a wide scope of branded generic medications, aesculapian devices, diagnostics, and nutritional items.

While we admit the imaginable of ABT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.